 Connection
Dolores Lamb to Prostatic Neoplasms
This is a "connection" page, showing publications Dolores Lamb has written about Prostatic Neoplasms.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
2.998 |
|
|
|
-
Scovell JM, Butler P, Ramasamy R, Lamb DJ. Words of wisdom. Re: Testosterone treatment is a potent tumor promoter for the rat prostate. Eur Urol. 2015 Apr; 67(4):814-5.
Score: 0.490
-
Kovac JR, Pan MM, Lipshultz LI, Lamb DJ. Current state of practice regarding testosterone supplementation therapy in men with prostate cancer. Steroids. 2014 Nov; 89:27-32.
Score: 0.468
-
Tannour-Louet M, Lewis SK, Louet JF, Stewart J, Addai JB, Sahin A, Vangapandu HV, Lewis AL, Dittmar K, Pautler RG, Zhang L, Smith RG, Lamb DJ. Increased expression of CYP24A1 correlates with advanced stages of prostate cancer and can cause resistance to vitamin D3-based therapies. FASEB J. 2014 Jan; 28(1):364-72.
Score: 0.442
-
Lamb DJ, Tannour-Louet M. In vivo exploration of the functional activity of the non-coding 8q24 prostate cancer risk locus. Asian J Androl. 2010 Nov; 12(6):787-9.
Score: 0.357
-
Lamb DJ, Zhang L. Challenges in prostate cancer research: animal models for nutritional studies of chemoprevention and disease progression. J Nutr. 2005 12; 135(12 Suppl):3009S-3015S.
Score: 0.257
-
Lamb DJ, Zhang L, Buttyan R. A problem with a chaperone. J Urol. 2005 May; 173(5):1455.
Score: 0.247
-
Lamb DJ, Puxeddu E, Malik N, Stenoien DL, Nigam R, Saleh GY, Mancini M, Weigel NL, Marcelli M. Molecular analysis of the androgen receptor in ten prostate cancer specimens obtained before and after androgen ablation. J Androl. 2003 Mar-Apr; 24(2):215-25.
Score: 0.212
-
Eisenberg ML, Li S, Betts P, Herder D, Lamb DJ, Lipshultz LI. Testosterone therapy and cancer risk. BJU Int. 2015 Feb; 115(2):317-21.
Score: 0.119
-
Shariat SF, Roehrborn CG, Lamb DJ, Slawin KM. Notice of duplicate publication: "Potentially harmful effect of a testosterone dietary supplement on prostate cancer growth and metastasis" (arch intern med. 2008;168[2]:235-236). Arch Intern Med. 2008 10 13; 168(18):2046-7.
Score: 0.078
-
Shariat SF, Lamb DJ, Roehrborn CG, Slawin KM. Potentially harmful effect of a testosterone dietary supplement on prostate cancer growth and metastasis. Arch Intern Med. 2008 Jan 28; 168(2):235-6.
Score: 0.075
-
Shariat SF, Lamb DJ, Iyengar RG, Roehrborn CG, Slawin KM. Herbal/hormonal dietary supplement possibly associated with prostate cancer progression. Clin Cancer Res. 2008 Jan 15; 14(2):607-11.
Score: 0.074
-
Shariat SF, Anwuri VA, Lamb DJ, Shah NV, Wheeler TM, Slawin KM. Association of preoperative plasma levels of vascular endothelial growth factor and soluble vascular cell adhesion molecule-1 with lymph node status and biochemical progression after radical prostatectomy. J Clin Oncol. 2004 May 01; 22(9):1655-63.
Score: 0.058
-
James AJ, Agoulnik IU, Harris JM, Buchanan G, Tilley WD, Marcelli M, Lamb DJ, Weigel NL. A novel androgen receptor mutant, A748T, exhibits hormone concentration-dependent defects in nuclear accumulation and activity despite normal hormone-binding affinity. Mol Endocrinol. 2002 Dec; 16(12):2692-705.
Score: 0.052
-
Shariat SF, Lamb DJ, Kattan MW, Nguyen C, Kim J, Beck J, Wheeler TM, Slawin KM. Association of preoperative plasma levels of insulin-like growth factor I and insulin-like growth factor binding proteins-2 and -3 with prostate cancer invasion, progression, and metastasis. J Clin Oncol. 2002 Feb 01; 20(3):833-41.
Score: 0.049
-
Khera M, Grober ED, Najari B, Colen JS, Mohamed O, Lamb DJ, Lipshultz LI. Testosterone replacement therapy following radical prostatectomy. J Sex Med. 2009 Apr; 6(4):1165-1170.
Score: 0.020
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|